DANish Patients With Atrial Fibrillation and Sleep Apnea Prevalence by Night Owl

Obstructive Sleep Apnea Clinical Trial

— DANAPNO  

Official title:

Danish Patients With Atrial Fibrillation and Sleep Apnea Prevalence by Night Owl

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04760002
• Other study ID #: P-2021-57
• Status: Completed
• Start date: January 25, 2021
• Est. completion date: January 1, 2023

Study information

• Verified date: March 2023
• Source: Herlev and Gentofte Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

A project of the feasibility of using NightOwl to detect the prevalence of obstructive sleep apnea (OSA) in patients with atrial fibrillation (AF). The long-term aim is to use the device to screen for OSA in a randomized clinical trial in AF patients undergoing ablation and/or a randomized trial of AF patients undergoing cardioversion.

Description:

Patients diagnosed with any type of AF referred to anticoagulation initiation at a nurse-run ambulatory will beasked to participate. The ambulatory consists of four daily nurse-led tracks at Department ofCardiology, Herlev-Gentofte University Hospital. In a formal collaboration, Department ofPulmonology, Herlev-Gentofte University Hospital provides work-up with cardio-respiratory monitoring investigation and clinical evaluation of initiating treatment of sleep apnea in patients referred from the study. ParticipantsParticipants with AF, without known sleep apnea, and indication for anticoagulation will be recruited from the Thrombosis unit (Tromboseklinikken) at Herlev-GentofteHospital. Participants will be contacted and asked of participation in the research project by a local investigator or a project nurse as part of their standard check at the anticoagulation outpatient clinic at Herlev and Gentofte Hospital. The conversation will include verbal participant information about the research project and about the right of time to consider recruitment. The written participant information will be handed to the participants prior to the verbal information, and it will be handed to the participants by a researcher with thorough knowledge to the project or a project nurse. The information needed for finding qualified participants, before a written informed consent is obtained, will be passed on to the investigators. The written informed consent allows the researchers to obtain necessary information for the project in the participant's medical health records

Study Design:

The is a cross sectional study. In total two visits will be planned, with a third visit for the first 20 participants and participants with apnea-hypopnea index (AHI)>15 included in the study.

1. Initial visit with time for clinical evaluation, questionnaire of OSA symptoms, theparticipant borrows a NightOwl and receive device instructions.

2. Four night of recording with NightOwl™ in home environment.

3. Follow-up visit for the home-monitoring results and soft node questionnaire.

4. For the 20 first patients and for all patients where the home test is showing (AHI>15) a fourth visit at the sleep apnea clinic will be arranged.

The time plan for the study inclusion until last patient enrolled are estimated to be approximately 6months

Recruitment information / eligibility

• Status: Completed
• Enrollment: 126
• Est. completion date: January 1, 2023
• Est. primary completion date: January 1, 2023
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of AF of any type

2. Age < 90 years

3. Age >18 years

Exclusion Criteria:

1. Known sleep apnea

2. Secondary AF (post-surgical, due to infection, thyroid-induced)

3. Known or newly discovered severe ventricular ectopic beats (as defined by the NightOwl manual)

4. Professional drivers

5. Severe heart failure (New York Heart Association class III or IV)

6. Severe chronic obstructive pulmonary disease (use of home oxygen)

Related Conditions & MeSH terms

• Apnea
• Atrial Fibrillation
• Obstructive Sleep Apnea
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Device:
• NightOwl
The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.

Locations

Country	Name	City	State
Denmark	Herlev-Gentofte Hospital	Copenhagen

Sponsors (2)

Lead Sponsor	Collaborator
Herlev and Gentofte Hospital	Sygekassernes Helsefond

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of obstructive sleep apnea in atrial fibrillation patients	The primary outcome of the study is the prevalence with 95% confidence intervals of obstructive sleep apnea in atrial fibrillation patients detected by NightOwl.	6 months
Secondary	Correlation between NightOwl and cardio-respiratory monitoring	The secondary outcome will be correlation between NightOwl and cardio-respiratory diagnostic testing for obstructive sleep apnea and correlation between obstructive sleep apnea screening questionnaire for cardio-respiratory and NightOwl.	6 months

External Links

•   Ectosense - NightOwl device